Clinical Trial Update: Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating defibrotide for liver damage due to veno-occlusive disease after peripheral stem cell transplantation; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Veno-occlusive Disease

Drugs mentioned

• Defibrotide (defibrotide)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Veno-occlusive Disease | Phase 2 | Status: COMPLETED